Venezuelan equine encephalitis virus (VEEV), a mosquito-borne alphavirus, causes periodic epizootics in equines and is a recognized biological defense threat for humans. There are currently no FDA-licensed vaccines against VEEV. We developed a candidate DNA vaccine expressing the E3-E2-6K-E1 genes of VEEV (pWRG/VEE) and performed a Phase 1 clinical study to assess the vaccine's safety, reactogenicity, tolerability, and immunogenicity when administered by intramuscular (IM) or intradermal (ID) electroporation (EP) using the Ichor Medical Systems TriGrid™ Delivery System. Subjects in IM-EP groups received 0.5mg (N=8) or 2.0mg (N=9) of pWRG/VEE or a saline placebo (N=4) in a 1.0ml injection. Subjects in ID-EP groups received 0.08mg (N=8) or 0.3mg (N=8) of DNA or a saline placebo (N=4) in a 0.15ml injection. Subjects were monitored for a total period of 360 days. No vaccine- or device-related serious adverse events were reported. Based on the results of a subject questionnaire, the IM- and ID-EP procedures were both considered to be generally acceptable for prophylactic vaccine administration, with the acute tolerability of ID EP delivery judged to be greater than that of IM-EP delivery. All subjects (100%) in the high and low dose IM-EP groups developed detectable VEEV-neutralizing antibodies after two or three administrations of pWRG/VEE, respectively. VEEV-neutralizing antibody responses were detected in seven of eight subjects (87.5%) in the high dose and five of eight subjects (62.5%) in the low dose ID-EP groups after three vaccine administrations. There was a correlation between the DNA dose and the magnitude of the resulting VEEV-neutralizing antibody responses for both IM and ID EP delivery. These results indicate that pWRG/VEE delivered by either IM- or ID-EP is safe, tolerable, and immunogenic in humans at the evaluated dose levels. Clinicaltrials.gov registry number NCT01984983.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2016.04.077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amplification-Free Attomolar Detection of Short Nucleic Acids with Upconversion Luminescence: Eliminating Nonspecific Binding by Hybridization Complex Transfer.
Anal Chem
January 2025
Department of Life Technologies/Biotechnology, Faculty of Technology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland.
The anti-Stokes emission of photon upconversion nanoparticles (UCNPs) facilitates their use as labels for ultrasensitive detection in biological samples as infrared excitation does not induce autofluorescence at visible wavelengths. The detection of extremely low-abundance analytes, however, remains challenging as it is impossible to completely avoid nonspecific binding of label conjugates. To overcome this limitation, we developed a novel hybridization complex transfer technique using UCNP labels to detect short nucleic acids directly without target amplification.
View Article and Find Full Text PDFCognitive Behavioural Therapy to Optimize Post-Operative Recovery (COPE): a randomized controlled feasibility trial in extremity fracture patients.
Pilot Feasibility Stud
January 2025
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Article Synopsis
- The study aimed to assess the feasibility of an online cognitive behavioral therapy (CBT) program for patients recovering from extremity fractures compared to usual care.
- Despite enrolling 94 participants, recruitment showed a "yellow light," indicating some success but needing improvements.
- Compliance with the CBT program was low, as only 60% completed all modules, leading to a "red light," suggesting significant changes are necessary before a larger trial can proceed.
Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study.
BMC Nephrol
January 2025
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Key Laboratory of Organ Transplantation, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Huazhong University of Science and Technology, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, China.
Background: Effective treatment of late antibody-mediated rejection (late AMR) is still an unmet medical need. Clearing donor-specific antibody (DSA) and preventing its rebound is the ideal goal of treatment.
Methods: We have summarized the clinical data from seven patients with late or chronic active AMR after renal transplantation who received daratumumab (Dara)-based treatment first (Phase 1) and then tocilizumab (TCZ) therapy (Phase 2).
Article Synopsis
- The study explores the effectiveness and safety of combining nivolumab, an immunotherapy drug, with chemotherapy in patients with a specific type of metastatic gastric cancer co-expressing FGFR2 and PD-L1.
- A total of 23 patients were treated, showing a 1-year progression-free survival (PFS) rate of 30.4% and a median overall survival (OS) of 15.1 months, though the primary endpoint of improved 1-year PFS was not achieved.
- The results highlight the need for future research on patient selection and potential combination therapies to enhance treatment outcomes in this patient population.
Improving spleen segmentation in ultrasound images using a hybrid deep learning framework.
Sci Rep
January 2025
School of Mechanical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
This paper introduces a novel method for spleen segmentation in ultrasound images, using a two-phase training approach. In the first phase, the SegFormerB0 network is trained to provide an initial segmentation. In the second phase, the network is further refined using the Pix2Pix structure, which enhances attention to details and corrects any erroneous or additional segments in the output.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!